United Therapeutics (NASDAQ:UTHR) Director Sells 228 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 228 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $505.87, for a total transaction of $115,338.36. Following the sale, the director owned 5,580 shares of the company’s stock, valued at approximately $2,822,754.60. The trade was a 3.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Trading Down 0.5%

UTHR traded down $2.35 on Tuesday, hitting $500.35. 1,326,943 shares of the company’s stock were exchanged, compared to its average volume of 496,432. The stock has a fifty day moving average of $520.02 and a two-hundred day moving average of $540.96. The firm has a market cap of $21.46 billion, a PE ratio of 17.90, a P/E/G ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a twelve month low of $397.00 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business posted $6.41 EPS. On average, analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in United Therapeutics during the 2nd quarter worth approximately $2,868,735,000. Jupiter Topco LLC bought a new position in shares of United Therapeutics during the second quarter worth $450,140,000. Norges Bank bought a new position in shares of United Therapeutics during the fourth quarter worth $293,418,000. Bank of New York Mellon Corp acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $159,522,000. Finally, Caisse de depot et placement du Quebec bought a new stake in shares of United Therapeutics in the 2nd quarter valued at $154,304,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.